Shift Bioscience
Leonard Wossnig is the Chief Technology Officer at LabGenius, where innovative antibody discovery merges synthetic biology, robotic automation, and machine learning. Under Wossnig's leadership, LabGenius is advancing a pipeline of immunotherapies for solid tumors and has released research on immune cell engagers. Wossnig holds multiple roles, including Fellow of the Royal Society of Biology and Scientific Advisor at Shift Bioscience. Previously, Wossnig served as Vice President of Artificial Intelligence at Odyssey Therapeutics and co-founded Rahko, leading the company to its acquisition. Wossnig has an extensive academic background, culminating in a PhD from UCL and experience as a teaching assistant in various computer science courses.
This person is not in any teams
Shift Bioscience
Shift Bioscience is unlocking safe rejuvenation with cell simulations. Cellular reprogramming is a powerful biological pathway that can reverse ageing and age-driven diseases in the dish but is not yet safe for clinical use. Our team based in Cambridge UK has pioneered the first high throughput, high accuracy ageing biomarker, which can be leveraged in AI-based cell simulations to identify drug targets for safe rejuvenation.